Less Peripheral Sensory Neuropathy with Shorter-term Oxaliplatin-based Chemotherapy Less Peripheral Sensory Neuropathy with Shorter-term Oxaliplatin-based Chemotherapy

Patients with advanced colon cancer face a lower risk of developing long-term peripheral sensory neuropathy (PSN) with a three-month rather than a six-month regimen of oxaliplatin-based adjuvant chemotherapy, according to results from the ACHIEVE phase 3 trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news